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The study by Hincker and colleagues indicated that the
perioperative use of rotational thrombelastometry
(ROTEM™) could predict thromboembolic events in 90%
of the cases in non-cardiac surgery. Viscoelastic tests
(VETs) - ROTEM™ and thrombelastography (TEG™) - are
used mainly to predict bleeding complications. Most
conventional coagulation tests, like prothrombin time
and activated partial thromboplastin time, can identify a
disturbance in plasmatic hemostasis. However, the
relevance of these assays is limited to the initiation
phase of coagulation, whereas VETs are designed to
assess the whole clotting kinetics and strength of the
whole blood clot and reflect more the interaction
between procoagulants, anticoagulants, and platelets.
The first reports about VET and hypercoagulable state
were published more than 25 years ago. Since then,
several studies with different quality and sample size
have been published, sometimes with conflicting
results. A systematic review about hypercoagulable state
and TEG™ indicated that further studies are needed to
recommend VETs as a screening tool to predict
postoperative thrombosis.In a previous issue of Critical Care, Hincker and colleagues
[1] identified with preoperative rotational thrombelastome-
try (ROTEM™, TEM International, München, Germany)
analysis patients at high risk for postoperative thrombo-
embolic events. Viscoelastic tests (VETs) were developed
primarily to detect coagulopathy rather than throm-
bosis. Hartert [2] established thrombelastography (TEG™,
Haemonetics, Braintree, MA, US) in 1948. Since that time,
TEG™ has had different periods of popularity but has
never been routinely used for perioperative coagulationCorrespondence: fuat.saner@uni-due.de
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in the 1980s [3].
ROTEM™ is a computerized point-of-care system, simi-
lar to TEG™ technologies, but its measurements are more
robust than those of TEG™, which enables ROTEM™ for a
mobile bedside testing (for example, in the operation
theatre or intensive care unit).
Bleeding and blood transfusion are associated with
increased mortality and morbidity [4]. VETs are able to
predict bleeding complications and to provide a goal-
directed coagulation treatment with fibrinogen concentrate,
crypoprecipitate, prothrombin complex, platelets, and
antifibrinolytic therapy instead of blind fresh frozen
plasma (FFP) transfusions, and this treatment avoids
negative side effects of FFPs, like transfusion-associated
lung injury, transfusion-associated circulation overload, or
infections [5]. Other benefits of ROTEM™ are the shorter
turnaround time (10 to 15 minutes [5]) compared with
conventional coagulation tests (45 to 90 minutes [6,7]).
Akay and colleagues [8] evaluated the efficacy of
ROTEM™ to detect hypercoagulopathy in cancer patients
compared with healthy controls. The authors indicated
that in all four tests - extrinsic thrombelastometry, intrin-
sic thrombelastometry, fibrinogen thrombelastometry, and
aprotinin thrombelastometry - the clot formation time
was significantly shorter and maximum clot formation
was significant higher compared with healthy controls, in-
dicating a risk for thrombosis. However, there were some
problems putting these findings into a clinical context; for
example, no data about the incidence of thromboembolic
events were provided.
In a cohort study, McCrath and colleagues [9] investi-
gated 240 consecutive patients scheduled for non-cardiac
surgery, to identify patients with increased risk for throm-
bosis with TEG™. The patients were stratified in two
groups; those with a maximum amplitude (MA) of greater
than 68 mm were assigned as hypercoagulable, and those
with an MA of not more than 68 mm were assigned as
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higher compared with those with an MA of not more
than 68 mm (8.4% versus 1.4%, P = 0.0157). Myocardial
infarction occurred only in patients with an increased
MA of greater than 68 mm.
Cerutti and colleagues [10] described a TEG™ detected
hypercoagulable state in adult living donors, despite
decreased platelet count, increased international normal-
ized ratio, and normal activated partial thromboplastin
time.
However, some other reports did not find a correlation
between hypercoagulability identified by TEG™ and post-
operative thrombotic complication [11,12]. Dai and col-
leagues [13] conducted a meta-analysis comparing several
studies performed with TEG™, supposing that TEG™ may
be useful to predict thromboembolic events postopera-
tively. However, because TEG™ technologies have changed
over the last 30 years, there is wide variability in TEG™
results in the different studies. As opposed to TEG™ mea-
surements, ROTEM™ measurements are more robust and
have an automated pipette, resulting in more reproducible
and precise results [14].
Outlook for the future
Although standard laboratory tests are poor predictors
for both bleeding and thrombosis, clinicians or laboratory
physicians are very reluctant to use VETs for global assess-
ment for bleeding or thrombosis. Although a Cochrane
meta-analysis [15] failed to show that the use of TEG™ or
ROTEM™ reduces mortality, at least one prospective
randomized trial shows that coagulation management-
guided ROTEM™ reduces blood loss and thromboembolic
events [16]. The study by Hincker and colleagues [1]
shows very encouraging results that ROTEM™ can predict
thrombotic complications in non-cardiac surgery. These
data should urge us to use more VETs for both bleeding
and risk for thrombosis, although these data should be
confirmed in a prospective randomized trial.
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